If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. Late last year, UK health and government officials announced the emergence of a new ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Experts from the University of Cambridge say that a mutation to a gene called DENND1B ... Around 58 per cent of women and 68 per cent of men in the UK are overweight or obese.

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Sequenom's MassARRAY ® system enables sensitive and rapid somatic mutation profiling in solid tumors or cell lines. Our validation studies revealed mutations in most of the oncogenes analyzed ...

Already, the mutation has been detected in a strain that has already spread from Africa to the UK. The health officials are calling on the international community to issue a strong response to ...

EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients remain untested due to logistical and resource constraints ...

The MARIPOSA trial randomly assigned 1074 patients with EGFR exon 19 deletion or exon 21 L858R substitution mutation–positive locally advanced or metastatic NSCLC and no prior systemic therapy ...

safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca ...

Of these, around 70% are diagnosed at an advanced stage and 15% have tumours with an EGFR mutation. If clinicians do reserve Tagrisso plus chemo for use in patients with a need for more intensive ...